Danoprevir monotherapy decreases inflammatory markers in patients with chronic hepatitis C virus infection.
about
Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 InfectionInfluence of chronic hepatitis C infection on cytochrome P450 3A4 activity using midazolam as an in vivo probe substrate.Peripheral blood HIV-1 DNA dynamics in antiretroviral-treated HIV/HCV co-infected patients receiving directly-acting antivirals.Patients with chronic hepatitis C receiving sofosbuvir and ribavirin-based treatment, with or without interferon in Zhejiang, China: An observational study
P2860
Danoprevir monotherapy decreases inflammatory markers in patients with chronic hepatitis C virus infection.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Danoprevir monotherapy decreas ...... c hepatitis C virus infection.
@ast
Danoprevir monotherapy decreas ...... c hepatitis C virus infection.
@en
type
label
Danoprevir monotherapy decreas ...... c hepatitis C virus infection.
@ast
Danoprevir monotherapy decreas ...... c hepatitis C virus infection.
@en
prefLabel
Danoprevir monotherapy decreas ...... c hepatitis C virus infection.
@ast
Danoprevir monotherapy decreas ...... c hepatitis C virus infection.
@en
P2093
P2860
P356
P1476
Danoprevir monotherapy decreas ...... c hepatitis C virus infection.
@en
P2093
Caralee J Schaefer
Jiing-Huey Lin
Karl Kossen
Patrick F Smith
Scott D Seiwert
Sharlene R Lim
Williamson Bradford
P2860
Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C
Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence
P304
P356
10.1128/AAC.00131-11
P407
P577
2011-04-18T00:00:00Z